February 26, 2018 / 11:24 PM / 10 months ago

BRIEF-Lilly Receives Additional FDA Approval For Verzenio​

Feb 26 (Reuters) - Eli Lilly And Co:

* LILLY RECEIVES ADDITIONAL FDA APPROVAL FOR VERZENIO (ABEMACICLIB), AS INITIAL TREATMENT FOR ADVANCED BREAST CANCER

* SAYS ‍NEW INDICATION BASED ON MONARCH 3 TRIAL CAN HELP MORE WOMEN LIVING WITH HR+, HER2- ADVANCED BREAST CANCER​

* SAYS ‍RECOMMENDED DOSE OF VERZENIO IN COMBINATION WITH AI IS 150 MG ORALLY TWICE DAILY, CONTINUED UNTIL DISEASE PROGRESSION/ UNACCEPTABLE TOXICITY​

* SAYS ‍VERZENIO IS AVAILABLE IN 4 TABLET STRENGTHS (200 MG, 150 MG, 100 MG, AND 50 MG)​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below